Hüsch Tanja, Kretschmer Alexander, Thomsen Frauke, Kronlachner Dominik, Kurosch Martin, Obaje Alice, Anding Ralf, Pottek Tobias, Rose Achim, Olianas Roberto, Friedl Alexander, Hübner Wilhelm, Homberg Roland, Pfitzenmaier Jesco, Grein Ulrich, Queissert Fabian, Naumann Carsten M, Schweiger Josef, Wotzka Carola, Nyarangi-Dix Joanne, Hofmann Torben, Ulm Kurt, Bauer Ricarda M, Haferkamp Axel
Department of Urology and Pediatric Urology, University Medical Center of Johannes Gutenberg University, Mainz, Germany.
Department of Urology, Ludwig-Maximilians-University, Campus Großhadern, Munich, Germany; Vancouver Prostate Center, University of British Columbia, Vancouver, Canada.
Urology. 2017 May;103:179-184. doi: 10.1016/j.urology.2016.12.056. Epub 2017 Jan 16.
To investigate the impact of the antibiotic coating InhibiZone on the infection and explantation rates of the AMS 800 in comparison to the AMS 800 without InhibiZone.
We retrospectively identified 305 patients with an AMS 800 in a multicenter cohort study. Patients were subsequently divided into InhibiZone and without InhibiZone-coated groups. Infection and explantation rates were analyzed by univariate and consecutively by multivariate logistic regression adjusted to variable risk factors. The infection-free interval was estimated by Kaplan-Meier plot and compared by the log-rank test. A P value below .05 was considered statistically significant.
We identified 47 patients with InhibiZone and 258 without InhibiZone coating. In univariate analysis, we could not identify a significant difference in infection (P = .932) or explantation (P = .715) rates between the groups. In multivariate analysis, impaired wound healing (P = .008) and urethral erosion (P < .001) were independent predictors for infection. The InhibiZone coating neither demonstrated significant influence on the infection rate (P = .534) nor on the explantation rate (P = .214). There was no significant difference in estimated infection-free survival between the groups (P = .265).
The antibiotic coating of the AMS 800 had no significant impact on infection or explantation rates in our cohort.
研究抗生素涂层InhibiZone对AMS 800感染率和植入物取出率的影响，并与未使用InhibiZone的AMS 800进行比较。
在一项多中心队列研究中，我们回顾性地确定了305例植入AMS 800的患者。随后将患者分为InhibiZone组和未使用InhibiZone涂层组。通过单因素分析，然后连续进行多因素逻辑回归分析，对可变风险因素进行调整，分析感染率和植入物取出率。通过Kaplan-Meier曲线估计无感染间隔时间，并通过对数秩检验进行比较。P值低于0.05被认为具有统计学意义。
我们确定了47例使用InhibiZone的患者和258例未使用InhibiZone涂层的患者。在单因素分析中，我们未发现两组之间在感染率（P = 0.932）或植入物取出率（P = 0.715）上存在显著差异。在多因素分析中，伤口愈合受损（P = 0.008）和尿道侵蚀（P < 0.001）是感染的独立预测因素。InhibiZone涂层对感染率（P = 0.534）和植入物取出率（P = 0.214）均未显示出显著影响。两组之间估计的无感染生存率无显著差异（P = 0.265）。
在我们的队列中，AMS 800的抗生素涂层对感染率或植入物取出率没有显著影响。
